ArticleTranslational cancer research2022
Establishment and validation of a novel nomogram for survival prediction of ovarian carcinosarcoma.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk factors and treatment strategies for female reproductive system carcinosarcoma with metastasis.Translational cancer research · 2025Article
- Nomograms to predict overall survival for patients with endometrial carcinosarcoma.Obstetrics & gynecology science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ovarian carcinosarcoma (OCS) is a rare and aggressive histological type of ovarian cancer. Current prognostic methods for OCS are insufficient. This study was undertaken to establish and validate a novel nomogram for predicting the overall survival (OS) of OCS patients. Methods: We extracted 820 patients with OCS from the Surveillance, Epidemiology, and End Results (SEER) database and further randomly assigned them to a training set (n=574) and a validation set (n=246) at a ratio of 7-to-3. Univariate and multivariate regression analyses were utilized to verity independent prognostic factors, and a prognostic nomogram was constructed based on the results. The performance of the new model was compared with that of the AJCC staging system using the area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), integrated discrimination improvement (IDI), calibration curve, and decision curve analysis (DCA). Results: Cox regression analysis suggested that age, grade, tumor size, the American Joint Committee on Cancer (AJCC) stage, surgery, and chemotherapy were the independent prognostic factors. These factors were integrated into a prognostic nomogram to determine the 1-, 3-, and 5-year OS of OCS patients. The AUC, NRI, IDI, calibration curves, and DCA data demonstrated that our nomogram had better discriminative ability than the AJCC staging system alone. The calibration curves indicate that the nomogram was well-calibrated. The DCA verified the clinical applicability of the nomogram. Conclusions: Our current study is the first to establish and internally validate a novel nomogram for predicting the 1-, 3-, and 5-year OS probabilities of OCS patients. Our prognostic nomogram was of good performance and can be an accurate tool to predict individualized survival time of OCS in clinical work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.